Interferons as Therapy for Viral and Neoplastic Diseases: From Panacea to Pariah to Paragon
Abstract
:1. Introduction
2. Clinical Uses of interferons
2.1. Use of IFN-α in chronic HCV infection
2.3. Use of interferons in treatment of neoplasms
2.4. Use of interferon in autoimmune disease and multiple sclerosis
3. Conclusions
References and Notes
- Isaacs, A.; Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B. Biol. Sci. 1957, 147, 258–267. [Google Scholar] [CrossRef] [PubMed]
- Tyrrell, D.A. Interferon produced by cultures of calf kidney cells. Nature 1959, 184 (Suppl. 7), 452–453. [Google Scholar] [CrossRef] [PubMed]
- Jones, B.R.; Galbraith, J.E.; Al-Hussaini, M.K. Effect of Interferon on Vaccination in Volunteers. Lancet 1962, 1, 873–875. [Google Scholar]
- Howie, J.W. Experiments with Interferon in Man: A Report to the Medical Research Council from the Scientific Committee on Interferon. Lancet 1965, 1, 505–506. [Google Scholar]
- Cantell, K.; Hirvonen, S.; Koistinen, V. Partial purification of human leukocyte interferon on a large scale. In Interferons Part A: Methods in Enzymology; Pestka, S., Ed.; Academic Press: New York, NY, USA, 1981; Volume 78, pp. 499–505. [Google Scholar]
- Merigan, T.C.; Reed, S.E.; Hall, T.S.; Tyrrell, D.A. Inhibition of respiratory virus infection by locally applied interferon. Lancet 1973, 1, 563–567. [Google Scholar]
- Sundmacher, R.; Neumann-Haefelin, D.; Cantell, K. Letter: Interferon treatment of dendritic keratitis. Lancet 1976, 1, 1406–1407. [Google Scholar]
- Arvin, A.M.; Feldman, S.; Merigan, T.C. Human leukocyte interferon in the treatment of varicella in children with cancer: a preliminary controlled trial. Antimicrob. Agents Chemother. 1978, 13, 605–607. [Google Scholar]
- Friedman, R.M.; Ramseur, J.M. Inhibition of murine leukemia virus production in chronically infected AKR cells: a novel effect of interferon. Proc. Natl. Acad. Sci. USA 1974, 71, 3542–3544. [Google Scholar]
- Greenberg, H.B.; Pollard, R.B.; Lutwick, L.I.; Gregory, P.B.; Robinson, W.S.; Merigan, T.C. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N. Engl. J. Med. 1976, 295, 517–522. [Google Scholar]
- Jacobs, L.; O'Malley, J.; Freeman, A.; Murawski, J.; Ekes, R. Intrathecal interferon in multiple sclerosis. Arch. Neurol. 1982, 39, 609–615. [Google Scholar]
- Quesada, J.R.; Swanson, D.A.; Trindade, A.; Gutterman, J.U. Renal cell carcinoma: Antitumor effects of leukocyte interferon. Cancer Res. 1983, 43, 940–947. [Google Scholar]
- Krown, S.E.; Burk, M.W.; Kirkwood, J.M.; Kerr, D.; Morton, D.L.; Oettgen, H.F. Human leukocyte (alpha) interferon in metastatic malignant melanoma: The American Cancer Society phase II trial. Cancer Treat. Rep. 1984, 68, 723–726. [Google Scholar]
- Merigan, T.C.; Sikora, K.; Breeden, J.H.; Levy, R.; Rosenberg, S.A. Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N. Engl. J. Med. 1978, 299, 1449–1453. [Google Scholar]
- Gresser, I.; Bourali, C. Antitumor effects of interferon preparations in mice. J. Natl. Cancer Inst. 1970, 45, 365–376. [Google Scholar]
- Strander, H.; Cantell, K.; Ingimarsson, S.; Jakobsson, P.A.; Nilsonne, U.; Soderberg, G. Exogenous interferon treatment of osteogenic sarcoma. Acta Orthop. Scand. 1974, 45 (Pt 6), 958–959. [Google Scholar]
- Nagata, S.; Taira, H.; Hall, A.; Johnsrud, L.; Streuli, M.; Ecsodi, J.; Boll, W.; Cantell, K.; Weissmann, C. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 1980, 284, 316–320. [Google Scholar] [PubMed]
- Taniguchi, T.; Guarente, L.; Roberts, T.M.; Kimelman, D.; Douhan, J., III.; Ptashne, M. Expression of the human fibroblast interferon gene in Escherichia coli. Proc. Natl. Acad. Sci. USA 1980, 77, 5230–5233. [Google Scholar] [CrossRef]
- Simonsen, C.C.; Shepard, H.M.; Gray, P.W.; Leung, D.W.; Pennica, D.; Yelverton, E.; Derynck, R.; Sherwood, P.J.; Sevinson, A.D.; Goeddel, D.V. Plasma-directed synthesis of human interferon-γ in E. coli and monkey cells. In Interferons; Merigan, T.C., Friedman, R.M., Eds.; Academic Press: New York, NY, USA, 1982; Volume 25, pp. 1–14. [Google Scholar]
- Panitch, H.; Goodin, D.S.; Francis, G.; Chang, P.; Coyle, P.K.; O'Connor, P.; Monaghan, E.; Li, D.; Weinshenker, B. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002, 59, 1496–1506. [Google Scholar]
- King, T.E., Jr.; Albera, C.; Bradford, W.Z.; Costabel, U.; Hormel, P.; Lancaster, L.; Noble, P.W.; Sahn, S.A.; Szwarcberg, J.; Thomeer, M.; Valeyre, D.; du Bois, R.M. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): A multicentre, randomised, placebo-controlled trial. Lancet 2009, 374, 222–228. [Google Scholar] [PubMed]
- Mennechet, F.J.; Uze, G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006, 107, 4417–4423. [Google Scholar]
- Robek, M.D.; Boyd, B.S.; Chisari, F.V. Lambda interferon inhibits hepatitis B and C virus replication. J. Virol. 2005, 79, 3851–3854. [Google Scholar]
- Hoofnagle, J.H.; Seeff, L.B. Peginterferon and ribavirin for chronic hepatitis C. N. Engl. J. Med. 2006, 355, 2444–2451. [Google Scholar]
- Dienstag, J.L. Hepatitis B virus infection. N. Engl. J. Med. 2008, 359, 1486–1500. [Google Scholar]
- Oh, T.S.; Rice, C.M. Predicting response to hepatitis C therapy. J. Clin. Invest. 2009, 119, 5–7. [Google Scholar]
- Fishman, S.L.; Factor, S.H.; Balestrieri, C.; Fan, X.; Dibisceglie, A.M.; Desai, S.M.; Benson, G.; Branch, A.D. Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin. Cancer Res. 2009, 15, 3205–3213. [Google Scholar]
- Foy, E.; Li, K.; Wang, C.; Sumpter, R., Jr.; Ikeda, M.; Lemon, S.M.; Gale, M., Jr. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300, 1145–1148. [Google Scholar] [PubMed]
- Tai, A.W.; Chung, R.T. Racial differences in response to interferon-based antiviral therapy for hepatitis C virus infection: A hardwiring issue? J. Infect. Dis. 2009, 199, 1101–1103. [Google Scholar] [CrossRef] [PubMed]
- Rodriguez-Torres, M.; Jeffers, L.J.; Sheikh, M.Y.; Rossaro, L.; Ankoma-Sey, V.; Hamzeh, F.M.; Martin, P. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N. Engl. J. Med. 2009, 360, 257–267. [Google Scholar]
- Di Bisceglie, A.M.; Shiffman, M.L.; Everson, G.T.; Lindsay, K.L.; Everhart, J.E.; Wright, E.C.; Lee, W.M.; Lok, A.S.; Bonkovsky, H.L.; Morgan, T.R.; Ghany, M.G.; Morishima, C.; Snow, K.K.; Dienstag, J.L. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med. 2008, 359, 2429–2441. [Google Scholar]
- Casato, M.; Lagana, B.; Antonelli, G.; Dianzani, F.; Bonomo, L. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 1991, 78, 3142–3147. [Google Scholar]
- McHutchison, J.G.; Lawitz, E.J.; Shiffman, M.L.; Muir, A.J.; Galler, G.W.; McCone, J.; Nyberg, L.M.; Lee, W.M.; Ghalib, R.H.; Schiff, E.R.; Galati, J.S.; Bacon, B.R.; Davis, M.N.; Mukhopadhyay, P.; Koury, K.; Noviello, S.; Pedicone, L.D.; Brass, C.A.; Albrecht, J.K.; Sulkowski, M.S. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009, 361, 580–593. [Google Scholar]
- Hoofnagle, J.H. A step forward in therapy for hepatitis C. N. Engl. J. Med. 2009, 360, 1899–1901. [Google Scholar]
- Maylin, S.; Martinot-Peignoux, M.; Moucari, R.; Boyer, N.; Ripault, M.P.; Cazals-Hatem, D.; Giuily, N.; Castelnau, C.; Cardoso, A.C.; Asselah, T.; Feray, C.; Nicolas-Chanoine, M.H.; Bedossa, P.; Marcellin, P. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008, 135, 821–829. [Google Scholar]
- Bacon, B.R.; Shiffman, M.L.; Mendes, F.; Ghalib, R.; Hassanein, T.; Morelli, G.; Joshi, S.; Rothstein, K.; Kwo, P.; Gitlin, N. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009, 49, 1838–1846. [Google Scholar]
- Traub, A.; Payees, B.; Reuveny, S.; Mizrahi, A. Interferon-albumin conjugate with conserved biological activity. J. Gen. Virol. 1981, 53, 389–392. [Google Scholar]
- Ganem, D.; Prince, A.M. Hepatitis B virus infection—Natural history and clinical consequences. N. Engl. J. Med. 2004, 350, 1118–1129. [Google Scholar]
- Marcellin, P.; Lau, G.K.; Bonino, F.; Farci, P.; Hadziyannis, S.; Jin, R.; Lu, Z.M.; Piratvisuth, T.; Germanidis, G.; Yurdaydin, C.; Diago, M.; Gurel, S.; Lai, M.Y.; Button, P.; Pluck, N. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004, 351, 1206–1217. [Google Scholar] [PubMed]
- Marcellin, P.; Heathcote, E.J.; Buti, M.; Gane, E.; de Man, R.A.; Krastev, Z.; Germanidis, G.; Lee, S.S.; Flisiak, R.; Kaita, K.; Manns, M.; Kotzev, I.; Tchernev, K.; Buggisch, P.; Weilert, F.; Kurdas, O.O.; Shiffman, M.L.; Trinh, H.; Washington, M.K.; Sorbel, J.; Anderson, J.; Snow-Lampart, A.; Mondou, E.; Quinn, J.; Rousseau, F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008, 359, 2442–2455. [Google Scholar]
- Lok, A.S.; Weller, I.V.; Karayiannis, P.; Brown, D.; Fowler, M.J.; Monjardino, J.; Thomas, H.C.; Sherlock, S. Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver 1984, 4, 45–49. [Google Scholar]
- Antman, K.; Chang, Y. Kaposi's sarcoma. N. Engl. J. Med. 2000, 342, 1027–1038. [Google Scholar]
- Hauschild, A.; Petres-Dunsche, C. Intralesional treatment of classical Kaposi sarcoma with interferon-alpha. Hautarzt 1992, 43, 789–791. [Google Scholar]
- Gerein, V.; Rastorguev, E.; Gerein, J.; Jecker, P.; Pfister, H. Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann. Otol. Rhinol. Laryngol. 2005, 114, 463–471. [Google Scholar]
- Scheinfeld, N.; Lehman, D.S. An evidence-based review of medical and surgical treatments of genital warts. Dermatol. Online J. 2006, 12, 5. [Google Scholar]
- Deunas, L.; Alcantud, V.; Alvarez, F.; Arteaga, J.; Benitez, A.; Bopuza, M.; Carniege, L.; Cartaya, B.; Comas, C.; Cotayo, R.; Escobar, H.; Fernandez, H.; Fernandez, M.; Fernandez, R.; Garcia, M.; Iznaga, N.; la, O.F.; Marquez, J.; Nordet, D.; Perez, J.; Quintero, J.; Redonavich, A.; Robeleco, M.; Rodriguez, H.; Strander, H. Use of interferon-alpha in laryngeal papillomatosis: Eight years of the Cuban national programme. J. Laryngol. Otol. 1997, 111, 134–140. [Google Scholar]
- Quesada, J.R.; Hersh, E.M.; Manning, J.; Reuben, J.; Keating, M.; Schnipper, E.; Itri, L.; Gutterman, J.U. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 1986, 68, 493–497. [Google Scholar]
- Talpaz, M.; McCredie, K.B.; Mavligit, G.M.; Gutterman, J.U. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983, 62, 689–692. [Google Scholar]
- Goldman, J.M.; Melo, J.V. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344, 1084–1086. [Google Scholar]
- Sipkins, D.A. Rendering the leukemia cell susceptible to attack. N. Engl. J. Med. 2009, 361, 1307–1309. [Google Scholar]
- Edwards, L.; Berman, B.; Rapini, R.P.; Whiting, D.A.; Tyring, S.; Greenway, H.T., Jr.; Eyre, S.P.; Tanner, D.J.; Taylor, E.L.; Peets, E. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. Arch. Dermatol. 1992, 128, 1486–1489. [Google Scholar]
- Kim, K.H.; Yavel, R.M.; Gross, V.L.; Brody, N. Intralesional interferon alpha-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: Revisited. Dermatol. Surg. 2004, 30, 116–120. [Google Scholar] [PubMed]
- Ji, J.; Shi, J.; Budhu, A.; Yu, Z.; Forgues, M.; Roessler, S.; Ambs, S.; Chen, Y.; Meltzer, P.S.; Croce, C.M.; Qin, L.X.; Man, K.; Lo, C.M.; Lee, J.; Ng, I.O.; Fan, J.; Tang, Z.Y.; Sun, H.C.; Wang, X.W. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 2009, 361, 1437–1447. [Google Scholar]
- Melichar, B.; Koralewski, P.; Ravaud, A.; Pluzanska, A.; Bracarda, S.; Szczylik, C.; Chevreau, C.; Filipek, M.; Delva, R.; Sevin, E.; Negrier, S.; McKendrick, J.; Santoro, A.; Pisa, P.; Escudier, B. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann. Oncol. 2008, 19, 1470–1476. [Google Scholar]
- Cohen, H.T.; McGovern, F.J. Renal-cell carcinoma. N. Engl. J. Med. 2005, 353, 2477–2490. [Google Scholar]
- Tsao, H.; Atkins, M.B.; Sober, A.J. Management of cutaneous melanoma. N. Engl. J. Med. 2004, 351, 998–1012. [Google Scholar]
- Drolet, B.A.; Esterly, N.B.; Frieden, I.J. Hemangiomas in children. N. Engl. J. Med. 1999, 341, 173–181. [Google Scholar]
- Kiladjian, J.J.; Cassinat, B.; Chevret, S.; Turlure, P.; Cambier, N.; Roussel, M.; Bellucci, S.; Grandchamp, B.; Chomienne, C.; Fenaux, P. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008, 112, 3065–3072. [Google Scholar]
- Nurden, A.T.; Nurden, P. Increasing the platelet count in chronic ITP. Lancet 2008, 371, 362–364. [Google Scholar]
- Brod, S.A. Ingested type I interferon: A potential treatment for autoimmunity. J. Interferon Cytokine Res. 2002, 22, 1153–1166. [Google Scholar]
- Jacobs, L.D.; Beck, R.W.; Simon, J.H.; Kinkel, R.P.; Brownscheidle, C.M.; Murray, T.J.; Simonian, N.A.; Slasor, P.J.; Sandrock, A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 2000, 343, 898–904. [Google Scholar] [CrossRef] [PubMed]
- Polman, C.H.; O'Connor, P.W.; Havrdova, E.; Hutchinson, M.; Kappos, L.; Miller, D.H.; Phillips, J.T.; Lublin, F.D.; Giovannoni, G.; Wajgt, A.; Toal, M.; Lynn, F.; Panzara, M.A.; Sandrock, A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354, 899–910. [Google Scholar]
- Kastrukoff, L.F.; Oger, J.J.; Hashimoto, S.A.; Sacks, S.L.; Li, D.K.; Palmer, M.R.; Koopmans, R.A.; Petkau, A.J.; Berkowitz, J.; Paty, D.W. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology 1990, 40, 479–486. [Google Scholar] [PubMed]
- Lai, C.L.; Yuen, M.F. Chronic hepatitis B--new goals, new treatment. N. Engl. J. Med. 2008, 359, 2488–2491. [Google Scholar]
© 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Friedman, R.M.; Contente, S. Interferons as Therapy for Viral and Neoplastic Diseases: From Panacea to Pariah to Paragon. Pharmaceuticals 2009, 2, 206-216. https://doi.org/10.3390/ph2030206
Friedman RM, Contente S. Interferons as Therapy for Viral and Neoplastic Diseases: From Panacea to Pariah to Paragon. Pharmaceuticals. 2009; 2(3):206-216. https://doi.org/10.3390/ph2030206
Chicago/Turabian StyleFriedman, Robert M., and Sara Contente. 2009. "Interferons as Therapy for Viral and Neoplastic Diseases: From Panacea to Pariah to Paragon" Pharmaceuticals 2, no. 3: 206-216. https://doi.org/10.3390/ph2030206